Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates.
Animals
Antibodies, Viral
/ blood
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Ebola Vaccines
/ administration & dosage
Ebolavirus
/ immunology
Female
Hemorrhagic Fever, Ebola
/ immunology
Immunization Schedule
Immunization, Secondary
Immunogenicity, Vaccine
Immunologic Memory
Macaca fascicularis
Time Factors
Vaccines, DNA
/ administration & dosage
CD4+
CD8+
Ebola
T-cell
boost
non-human primates
prime
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
11
2020
accepted:
19
02
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost immunization has been demonstrated to protect non-human primates against a lethal challenge of Ebola virus, a pathogen that causes fatal hemorrhagic disease in humans. This protection correlates with antibody responses and is also associated with IFNγ
Identifiants
pubmed: 33790899
doi: 10.3389/fimmu.2021.627688
pmc: PMC8006325
doi:
Substances chimiques
Antibodies, Viral
0
Ebola Vaccines
0
Vaccines, DNA
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
627688Informations de copyright
Copyright © 2021 Marcus, Thompson, Zhou, Bailey, Donaldson, Stanley, Asiedu, Foulds, Roederer, Moliva and Sullivan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Opin Immunol. 2015 Aug;35:131-6
pubmed: 26247875
J Virol. 2003 Nov;77(21):11563-77
pubmed: 14557642
Lancet Infect Dis. 2011 Dec;11(12):916-24
pubmed: 21975270
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
EMBO Mol Med. 2014 May 06;6(6):708-20
pubmed: 24803000
J Virol. 2003 Jan;77(1):799-803
pubmed: 12477888
J Virol. 2002 Jun;76(12):6138-46
pubmed: 12021347
PLoS One. 2011;6(9):e24517
pubmed: 21931737
J Infect Dis. 2013 Sep;208(6):1008-19
pubmed: 23776192
PLoS One. 2015 Apr 09;10(4):e0122835
pubmed: 25856308
J Infect Dis. 2013 Aug 1;208(3):418-22
pubmed: 23633407
J Virol. 2003 Dec;77(23):12764-72
pubmed: 14610198
Annu Rev Immunol. 2000;18:927-74
pubmed: 10837079
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
J Virol. 2011 May;85(9):4222-33
pubmed: 21325402
Nature. 2000 Nov 30;408(6812):605-9
pubmed: 11117750
J Virol. 2013 Jul;87(13):7708-16
pubmed: 23637419
J Immunol Methods. 2006 Jun 30;313(1-2):199-208
pubmed: 16756987
Expert Rev Vaccines. 2012 Feb;11(2):189-209
pubmed: 22309668
Biotechnol J. 2013 Nov;8(11):1315-22
pubmed: 23813782
Science. 2001 Apr 6;292(5514):69-74
pubmed: 11393868
Adv Exp Med Biol. 2011;780:69-83
pubmed: 21842366
J Immunol. 2010 Dec 1;185(11):7097-106
pubmed: 21041730
PLoS Pathog. 2010 May 20;6(5):e1000904
pubmed: 20502688
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
PLoS One. 2012;7(6):e39075
pubmed: 22720032
J Virol. 2012 Jun;86(12):6970-8
pubmed: 22496212
J Virol. 2003 Sep;77(18):10113-8
pubmed: 12941922
J Virol. 2013 May;87(9):5151-60
pubmed: 23449790
J Virol. 2001 Mar;75(5):2462-7
pubmed: 11160750
Mol Med. 1999 Apr;5(4):224-31
pubmed: 10448644
J Infect Dis. 2010 Feb 15;201(4):600-7
pubmed: 20078213
PLoS One. 2011;6(8):e21225
pubmed: 21857901
J Virol. 2010 Oct;84(19):10386-94
pubmed: 20660192
Vaccine. 2009 Jul 30;27(35):4857-66
pubmed: 19520196
J Virol. 2003 Jun;77(11):6305-13
pubmed: 12743287
Clin Vaccine Immunol. 2013 Mar;20(3):397-408
pubmed: 23345581
J Immunol. 2005 Jan 1;174(1):449-55
pubmed: 15611270
Nat Rev Microbiol. 2009 May;7(5):393-400
pubmed: 19369954
PLoS One. 2010 Sep 21;5(9):e12873
pubmed: 20877623
J Infect Dis. 2013 Aug 1;208(3):413-7
pubmed: 23633404
J Virol. 1999 Sep;73(9):7524-32
pubmed: 10438842
Vaccine. 2011 Oct 6;29(43):7483-90
pubmed: 21839132
Vaccine. 2009 Jul 16;27(33):4468-74
pubmed: 19450644
J Infect Dis. 2011 Mar 1;203(5):610-9
pubmed: 21282192
PLoS One. 2010 Feb 02;5(2):e9015
pubmed: 20126394
Nat Med. 2011 Aug 21;17(9):1128-31
pubmed: 21857654
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
J Virol. 2005 Dec;79(24):15547-55
pubmed: 16306625
Vaccine. 2012 Feb 21;30(9):1737-45
pubmed: 22178526
Science. 2000 Oct 20;290(5491):486-92
pubmed: 11039923
Swiss Med Wkly. 2017 Aug 14;147:w14465
pubmed: 28804866
Immunol Rev. 2011 Jan;239(1):62-84
pubmed: 21198665
Sci Transl Med. 2014 Nov 5;6(261):261ra153
pubmed: 25378645
J Immunol. 2011 Sep 15;187(6):3391-401
pubmed: 21844392
Vaccine. 2011 Oct 26;29(46):8417-28
pubmed: 21864626